DrugPatentWatch Database Preview

Heron Theraps Inc Company Profile

« Back to Dashboard

What is the competitive landscape for HERON THERAPS INC, and what generic alternatives to HERON THERAPS INC drugs are available?

HERON THERAPS INC has two approved drugs.

There are eleven US patents protecting HERON THERAPS INC drugs.

Summary for Heron Theraps Inc

US Patents:	11
Tradenames:	2
Ingredients:	2
NDAs:	2

Drugs and US Patents for Heron Theraps Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Heron Theraps Inc	SUSTOL	granisetron	INJECTION, EXTENDED RELEASE;SUBCUTANEOUS	022445-001	Aug 9, 2016		RX	Yes	Yes
Heron Theraps Inc	SUSTOL	granisetron	INJECTION, EXTENDED RELEASE;SUBCUTANEOUS	022445-001	Aug 9, 2016		RX	Yes	Yes	8,715,710		Y
Heron Theraps Inc	SUSTOL	granisetron	INJECTION, EXTENDED RELEASE;SUBCUTANEOUS	022445-001	Aug 9, 2016		RX	Yes	Yes	6,613,355		Y
Heron Theraps Inc	CINVANTI	aprepitant	EMULSION;INTRAVENOUS	209296-001	Nov 9, 2017		RX	Yes	Yes	9,974,742		Y
Heron Theraps Inc	CINVANTI	aprepitant	EMULSION;INTRAVENOUS	209296-001	Nov 9, 2017		RX	Yes	Yes	9,561,229		Y
Heron Theraps Inc	CINVANTI	aprepitant	EMULSION;INTRAVENOUS	209296-001	Nov 9, 2017		RX	Yes	Yes	9,974,793		Y

Non-Orange Book US Patents for Heron Theraps Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
6,861,068	Pharmaceutical compositions using semi-solid delivery vehicle
8,252,306	Process for preparing a semi-solid delivery vehicle comprising granisetron

International Patents for Heron Theraps Inc Drugs

Country	Document Number	Estimated Expiration
South Korea	20070083851
Japan	2012107064
Spain	2529574
Hong Kong	1213477
European Patent Office	1796629
Japan	2008514646

Supplementary Protection Certificates for Heron Theraps Inc Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C0019	France		PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111
C/GB04/011	United Kingdom		PRODUCT NAME: APREPITANT, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/03/262/001 20031113; UK EU/1/03/262/002 20031113; UK EU/1/03/262/003 20031113; UK EU/1/03/262/004 20031113; UK EU/1/03/262/005 20031113; UK EU/1/03/262/006 20031113
2004	Austria		PRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111
2004002,C0734381	Lithuania		PRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111
C/GB08/021	United Kingdom		PRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111
C0010	France		PRODUCT NAME: APREPITANT; REGISTRATION NO/DATE: EU/1/03/262/001 20031111

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Heron Theraps Inc